High SEPT9_i1 protein expression is associated with high-grade prostate cancers

PLoS One. 2015 Apr 21;10(4):e0124251. doi: 10.1371/journal.pone.0124251. eCollection 2015.

Abstract

Septins are a family of GTP-binding cytoskeleton proteins expressed in many solid tumors. Septin 9 (SEPT9) in particular was found overexpressed in diverse carcinomas. Herein, we studied the expression of SEPT9 isoform 1 protein (SEPT9_i1) in human prostate cancer specimens. We utilized immunohistochemical staining to study the expression of SEPT9_i1 protein. Staining level was analyzed in association with clinical characteristics and the pathological Gleason grade and score. Fifty human prostate cancer specimens (42 primary tumors and 8 metastatic lesions) were stained by SEPT9_i1 antibody and analyzed. SEPT9_i1 protein was expressed in prostate cancer cells but absent in normal epithelial cells. The intensity of staining was correlated proportionally to pretreatment prostate-specific antigen (PSA) blood levels and Gleason score (P < 0.05). SEPT9_i1 was highly expressed in all metastatic lesions. A significant assocation between SEPT9_i1 expression and high Gleason score on multivariate linear regression analysis was found. We conclude that SEPT9_i1 is expressed in high-grade prostate tumors suggesting it has a significant role in prostate tumorigenesis and that it could serve as a molecular marker for prostate tumor progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / enzymology*
  • Adenocarcinoma / secondary
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism*
  • Bone Neoplasms / enzymology*
  • Bone Neoplasms / secondary
  • Disease Progression
  • Humans
  • Isoenzymes / metabolism
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Prostatic Neoplasms / enzymology*
  • Prostatic Neoplasms / pathology
  • Retrospective Studies
  • Septins / metabolism*

Substances

  • Biomarkers, Tumor
  • Isoenzymes
  • SEPTIN9 protein, human
  • Septins

Grants and funding

This work was supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.